ClinicalTrials.gg
CompletedNCT03801733Updated Mar 22, 2019

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

A Phase 1 interventional study of Vadadustat and Simvastatin in Drug Interaction Potentiation, sponsored by Akebia Therapeutics. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-22.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2018, 7 years 11 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jun 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.

Read the detailed description

This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin in healthy male and female subjects. Thirty-four (34) subjects will be enrolled in Part 1 (rosuvastatin) and based on review of the PK and safety/tolerability data, a decision will be made on whether to proceed with Part 2. Part 2 consists of 2 arms (sulfasalazine and pravastatin). Twenty-six (26) subjects will be enrolled into each arm. Part 3 consists of 2 arms (atorvastatin and simvastatin). Twenty-four (24) subjects will be enrolled into each arm after enrollment in Part 2 is completed. Subjects will be in the study for up to 72 days, including a 28-day screening period, 6-14 day in clinic period, and a 30-day follow up period post last dose. Blood samples for PK analysis will be collected at pre-defined time points throughout the study.

02

Conditions studied

  • Drug Interaction Potentiation

Keywords

  • Vadadustat
  • Normal Healthy volunteers
  • Pharmacokinetics
  • Rosuvastatin
  • Sulfasalazine
  • Pravastatin
  • Atrovastatin
  • Simvastatin
03

In context

Lead sponsor

Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Male or female between 18 and 55 years of age, inclusive, at time of
  • between 18.0 and 30.0 kg/m2, with a minimum body weight of 45 kg for females and 50 kg for males, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease. History of cancer (except treated non-melanoma skin cancer) or history of chemotherapy use within 5 years prior to Screening; History of latent or active tuberculosis (TB).
  • Positive test results for (HIV) antibody; 12. Positive test results of surface antigen (HBsAg), or positive virus antibody (HCVab) within 3 months prior to screening, or positive test results for human immunodeficiency virus antibody (HIVab) at Screening
  • Taking any prescription medication or over the counter multi-vitamin supplement, or any non-prescription products (including herbal-containing preparations but excluding acetaminophen) within 14 days prior to Day -1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Rosuvastatin, Vadadustat

    Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.

    Drug: Vadadustat · Drug: Rosuvastatin

  • Experimental
    Sulfasalazine. Pravastatin, Vadadustat

    Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design. Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.

    Drug: Vadadustat · Drug: Pravastatin · Drug: Sulfasalazine

  • Experimental
    Atorvastatin, Simvastatin, Vadadustat

    Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design. Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.

    Drug: Vadadustat · Drug: Simvastatin · Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) of rosuvastatin, sulfasalazine, pravastatin and simvastatin

    Time frame: Up to 10 weeks

  2. Area under plasma concentration-time curve from time 0 to infinity (AUCinf) of rosuvastatin, sulfasalazine, pravastatin and simvastatin

    Time frame: Up to 10 weeks

  3. Maximum observed plasma concentration (Cmax) of rosuvastatin. sulfasalazine, pravastatin, atorvastatin and simvastatin

    Time frame: Up to 10 weeks

  4. Area under plasma concentration-time curve (AUCtau) of atorvastatin

    Time frame: Up to 10 weeks

Secondary outcomes

  1. Time to maximum observed plasma concentration (Tmax) of rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin

    Time frame: Up to 10 weeks

  2. Elimination rate constant (Kel) of rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin

    Time frame: Up to 10 weeks

  3. Terminal half-life (t½) of rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin

    Time frame: Up to 10 weeks

  4. Apparent total body clearance (CL/F) of rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin

    Time frame: Up to 10 weeks

  5. Percentage of extrapolated area under the curve from time t to infinity (%AUCextrap or Residual Area) of rosuvastatin, sulfasalazine, pravastatin, atorvastatin, and simvastatin

    Time frame: Up to 10 weeks

  6. Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  7. Area under plasma concentration-time curve from time 0 to infinity (AUCinf) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  8. Maximum observed plasma concentration (Cmax) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  9. Time to maximum observed plasma concentration (Tmax) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  10. Elimination rate constant (Kel) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  11. Terminal half-life (t½) of sulfasalazine metabolites, sulfapyridine and 5-ASA (mesalamine

    Time frame: Up to 10 weeks

  12. Area under the plasma concentration-time curve for a dosing interval (AUCtau) of atorvastatin metabolites, o-hydroxyatorvastatin; p-hydroxyatorvastatin

    Time frame: Up to 10 weeks

  13. Maximum observed plasma concentration (Cmax) of atorvastatin metabolites, o-hydroxyatorvastatin; p-hydroxyatorvastatin

    Time frame: Up to 10 weeks

  14. Time to maximum observed plasma concentration (Tmax) of atorvastatin metabolites, o-hydroxyatorvastatin; p-hydroxyatorvastatin

    Time frame: Up to 10 weeks

  15. Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) of simvastatin metabolite

    Time frame: Up to 10 weeks

  16. Area under plasma concentration-time curve from time 0 to infinity (AUCinf) of simvastatin metabolite

    Time frame: Up to 10 weeks

  17. Maximum observed plasma concentration (Cmax) of simvastatin metabolite

    Time frame: Up to 10 weeks

  18. Time to maximum observed plasma concentration (Tmax) of simvastatin metabolite

    Time frame: Up to 10 weeks

  19. Elimination rate constant (Kel) of simvastatin metabolite

    Time frame: Up to 10 weeks

  20. Terminal half-life (t½), of simvastatin metabolite

    Time frame: Up to 10 weeks

  21. Reporting of treatment emergent adverse events (TEAE) as reported by the study subjects

    Time frame: Up to 10 weeks

07

Study locations

1 site
  • InVentiv Health Clinique Inc.
    Québec, Quebec G1P A02, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Nov 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2018
First posted
Jan 11, 2019
StartActual
Jun 17, 2018
Primary completionActual
Nov 24, 2018
CompletionActual
Nov 24, 2018
Last update
Mar 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03801733
Responsible party
Sponsor
First posted
Jan 11, 2019
Start date
Jun 17, 2018
Primary completion
Nov 24, 2018
Completion
Nov 24, 2018
Last update
Mar 22, 2019

Study contacts

Akebia Inc
study director · Akebia Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vadadustat · Simvastatin · Atorvastatin · Pravastatin · Sulfasalazine

Start the discussion